Clinical Profile for Lecanemab Subcutaneous Formulation for Treatment Initiation and Maintenance in Early Alzheimer’s Disease (AD)

The Lecanemab Clarity AD Open-label Extension in Early Alzheimer’s Disease: Initial Findings from the 48-month Analysis

The First Light: Efficacy and Safety of a Multi-dose Study of Oveporexton (TAK-861), an Oral Orexin Receptor Two Agonist for the Treatment of Narcolepsy Type One

Cognitive Health Social Disparities in Shawi Indigenous Communities of the Peruvian Amazon: A Preliminary Analysis